Allergan plc Company Profile (NYSE:ACT)

About Allergan plc (NYSE:ACT)

Allergan plc logoActavis, Inc. formerly Watson Pharmaceuticals, Inc., is a integrated global specialty pharmaceutical company engaged in the development, manufacturing, marketing, sale and distribution of generic, branded generic, brand, biosimilar and over-the-counter (OTC) pharmaceutical products. The Company also develops and out-licenses generic pharmaceutical products primarily in Europe through its Medis third-party business. The Company operates in three segments: Actavis Pharma, Actavis Specialty Brands and Anda Distribution. On January 23, 2013, the Company completed the acquisition of Uteron Pharma SA. On October 29, 2012, the Company sold its Rugby OTC pharmaceutical products and trademarks to The Harvard Drug Group, L.L.C. On January 24, 2012, the Company completed the acquisition of Ascent Pharmahealth Ltd.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Pharmaceuticals
  • Sub-Industry: Pharmaceuticals
  • Symbol: NYSE:ACT
  • CUSIP: 00507K10
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $297.00
  • 200 Day Moving Avg: $285.00
  • 52 Week Range: $202.00 - $318.00
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 14.24
  • P/E Growth: 0
  • Average Volume: 2.77 million shs.

Frequently Asked Questions for Allergan plc (NYSE:ACT)

What is Allergan plc's stock symbol?

Allergan plc trades on the New York Stock Exchange (NYSE) under the ticker symbol "ACT."

How were Allergan plc's earnings last quarter?

Allergan plc (NYSE:ACT) issued its quarterly earnings data on Wednesday, February, 18th. The company reported $3.91 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $3.67 by $0.24. The business had revenue of $4.01 billion for the quarter, compared to analyst estimates of $3.84 billion. The business's quarterly revenue was up 44.2% compared to the same quarter last year. During the same period in the previous year, the business posted $3.17 EPS. View Allergan plc's Earnings History.

Who are some of Allergan plc's key competitors?

How do I buy Allergan plc stock?

Shares of Allergan plc can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allergan plc's stock price today?

One share of Allergan plc stock can currently be purchased for approximately $299.00.

MarketBeat Community Rating for Allergan plc (NYSE ACT)
Community Ranking:  3.8 out of 5 (star star star)
Outperform Votes:  354 (Vote Outperform)
Underperform Votes:  116 (Vote Underperform)
Total Votes:  470
MarketBeat's community ratings are surveys of what our community members think about Allergan plc and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Allergan plc (NYSE:ACT) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A

Analysts' Ratings History for Allergan plc (NYSE:ACT)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/28/2016Leerink SwannBoost Price TargetOutperform$180.00 -> $215.00N/AView Rating Details
11/2/2015Susquehanna Bancshares IncBoost Price TargetPositive$290.00 -> $325.00N/AView Rating Details
(Data available from 9/21/2015 forward)


Earnings History for Allergan plc (NYSE:ACT)
Earnings by Quarter for Allergan plc (NYSE:ACT)
Earnings History by Quarter for Allergan plc (NYSE ACT)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/11/2015Q115$3.84$4.30$4.04 billion$4.23 billionViewListenView Earnings Details
2/18/2015Q414$3.67$3.91$3.84 billion$4.01 billionViewN/AView Earnings Details
11/5/2014Q314$3.10$3.19$3.63 billion$3.68 billionViewN/AView Earnings Details
8/5/2014Q214$3.36$3.42$2.55 billion$2.67 billionViewN/AView Earnings Details
4/30/2014Q114$3.23$3.49$2.59 billion$2.66 billionViewListenView Earnings Details
2/20/2014Q413$3.05$3.17$2.68 billion$2.78 billionViewListenView Earnings Details
10/29/2013Q313$2.09$2.09$2.04 billion$2.01 billionViewListenView Earnings Details
7/25/2013Q2 2013$2.00$2.01$1.99 billion$1.99 billionViewListenView Earnings Details
5/2/2013Q1 2013$1.86$1.99$1.97 billion$1.90 billionViewListenView Earnings Details
2/19/2013Q4 2012$1.53$1.59$1.74 million$1.75 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for Allergan plc (NYSE:ACT)
Current Year EPS Consensus Estimate: $18 EPS
Next Year EPS Consensus Estimate: $21 EPS


Dividend History for Allergan plc (NYSE:ACT)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for Allergan plc (NYSE:ACT)
Insider Trades by Quarter for Allergan plc (NYSE:ACT)
Insider Trades by Quarter for Allergan plc (NYSE:ACT)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
6/9/2015Nesli BasgozDirectorSell2,200$297.89$655,358.00View SEC Filing  
11/26/2014William MeuryInsiderSell4,550$269.14$1,224,587.00View SEC Filing  
9/8/2014Albert Paonessa IIIInsiderSell6,642$230.49$1,530,914.58View SEC Filing  
9/16/2013Albert HummelDirectorSell6,200$137.81$854,422.00View SEC Filing  
9/4/2013George Fred WilkinsonInsiderSell16,749$138.00$2,311,362.00View SEC Filing  
9/4/2013Jack MichelsonDirectorSell6,064$139.54$846,170.56View SEC Filing  
8/29/2013David BuchenInsiderSell10,000$135.56$1,355,600.00View SEC Filing  
8/26/2013Albert HummelDirectorSell40,000$134.44$5,377,600.00View SEC Filing  
8/20/2013Paul BisaroCEOSell50,000$135.30$6,765,000.00View SEC Filing  
8/15/2013Albert Paonessa IIIInsiderSell5,476$135.89$744,133.64View SEC Filing  
8/14/2013R Todd JoyceCFOSell15,000$137.98$2,069,700.00View SEC Filing  
8/13/2013Albert HummelDirectorSell10,000$133.85$1,338,500.00View SEC Filing  
8/12/2013Cathy KlemaDirectorSell1,667$133.03$221,761.01View SEC Filing  
8/12/2013David BuchenInsiderSell17,000$133.03$2,261,510.00View SEC Filing  
8/9/2013Ronald TaylorDirectorSell5,000$135.14$675,700.00View SEC Filing  
8/5/2013Charles EbertVPSell8,244$136.25$1,123,245.00View SEC Filing  
8/5/2013Michel FeldmanDirectorSell10,000$136.94$1,369,400.00View SEC Filing  
8/2/2013Robert StewartInsiderSell14,564$136.02$1,980,995.28View SEC Filing  
3/14/2013Charles M MayrInsiderSell1,000$91.77$91,770.00View SEC Filing  
3/12/2013Michael J FedidaDirectorSell8,000$89.00$712,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for Allergan plc (NYSE:ACT)
Latest Headlines for Allergan plc (NYSE:ACT)
DateHeadline logoPrescriber's Choice and Sincerus FL Release a Statement Regarding Allergan Lawsuit - PR Newswire (press release) - September 20 at 3:22 PM logoAllergan plc Ordinary Shares (AGN) May Have Just Saved Itself Billions - - September 14 at 3:24 PM logoAllergan Launches New Brilliant Distinctions®... - September 13 at 1:45 AM logoAllergan Protects Shareholders With Sovereign Immunity Deal - Seeking Alpha - September 12 at 3:31 PM logoApricus Biosciences, Inc.: Apricus Biosciences Announces $3.7 Million Private Placement Priced At-The-Market - September 12 at 2:05 AM logoAllergan and Saint Regis Mohawk Tribe Announce Agreements Regarding RESTASIS® Patents - PR Newswire (press release) - September 10 at 3:20 PM logoAllergan Files Suits Against Imprimis Pharmaceuticals, Inc., Prescriber's Choice, Inc., and Sincerus Florida, LLC - PR Newswire (press release) - September 9 at 8:36 PM logoUroGen Pharma Strengthens Management Team with the Appointment of Paul Chu as Vice President of Business ... - GlobeNewswire (press release) - September 7 at 1:25 AM logoAllergan to Present New Data on Chronic Migraine at the International Headache Congress in Vancouver - September 6 at 3:24 PM logoAnother Opioid Investigation For Mallinckrodt - Seeking Alpha - September 5 at 3:42 PM logoMallinckrodt added to Missouri attorney general's probe of opioid manufacturers - September 1 at 1:24 AM logoApricus Biosciences Announces FDA Acknowledgement of Vitaros(TM) Class 2 NDA Resubmission - Nasdaq - August 31 at 8:23 PM logoApricus Biosciences Announces FDA Acknowledgement of Vitaros™ Class 2 NDA Resubmission - Nasdaq - August 31 at 3:20 PM logoJim Cramer Advises His Viewers On Domino's Pizza, Allergan And More - Benzinga - August 31 at 3:20 PM logoMore Drugmakers Get Subpoenas From Missouri Attorney General - Bloomberg - August 30 at 11:50 PM logoApricus Biosciences Files NDA Resubmission for Vitaros™ - Nasdaq - August 30 at 1:51 AM logoApricus Biosciences Files NDA Resubmission for Vitaros(TM) - Nasdaq - August 29 at 3:46 PM logoAllergan to Present at the 2017 Wells Fargo Healthcare Conference - PR Newswire (press release) - August 16 at 3:25 PM logoWRAPUP 2-Big-name U.S. hedge funds shed healthcare stocks during the rally in Q2 - August 15 at 3:47 PM logoUroGen Pharma Reports Second Quarter 2017 Financial Results and Recent Corporate Developments - GlobeNewswire (press release) - August 14 at 8:45 PM logoDrugmaker Teva looks to sell Medis business to help cut debt - August 9 at 3:42 PM logoPro-Trader Daily: Corporate News Blog - Mallinckrodt to Acquire InfaCare Pharmaceutical and its Developmental Product Stannsoporfin - August 7 at 4:26 PM logoAllergan Plc (AGN) Q2 2017 Results - Earnings Call Transcript - August 3 at 3:56 PM logoAllergan Announces Third Quarter 2017 Cash Dividend of $0.70 Per Ordinary Share - August 2 at 3:23 PM logoPfizer CEO Read Dashes Hopes for Big M&A in Near Future - August 1 at 3:46 PM logoAmgen And Allergan Submit Biosimilar Biologics License Application For ABP 980 To US Food And Drug Administration - July 31 at 3:39 PM logoUROGEN PHARMA LTD. - - July 19 at 8:46 PM logoJoseph H. Boccuzi Appointed to Allergan plc Board of Directors - July 19 at 3:46 PM logoIs the Mayne Pharma Group Ltd share price too cheap to ignore? - July 18 at 8:49 PM logoAmgen (AMGN), Allergan (AGN) to Discuss Data Supporting BLA For ABP 215 with FDA - - July 13 at 9:05 PM logoAmgen And Allergan To Discuss Data Supporting Biologics License Application For ABP 215, A Biosimilar Candidate ... - PR Newswire (press release) - July 13 at 3:54 PM logoAllergan Lends Support to Broaden Uterine Fibroid Awareness Month - PR Newswire (press release) - July 13 at 3:54 PM logoAs Treasury Moves to Bring Back Inversions, Here are 7 of the Biggest Recent Deals - - July 11 at 9:31 PM logoAllergan Reports New Data Reinforcing the Effectiveness of Viberzi® (Eluxadoline) to Treat the Symptoms Associated ... - PR Newswire (press release) - July 10 at 8:31 PM logoEli Lilly Wins Cancer Drug Patent Case at U.K. Supreme Court - July 7 at 4:46 PM logoEli Lilly says UK Supreme Court ruled in its favor on Alimta vitamin regiment patents - July 7 at 4:46 PM logoUK Supreme Court Rules in Lilly's Favor: Actavis Infringed on European Vitamins Patents - July 7 at 4:46 PM logoUK Supreme Court rules in Eli Lilly's favor in drug dispute - July 7 at 4:46 PM logoUK Supreme Court rules in favor of Lilly's Alimta patents - July 7 at 4:46 PM logoOklahoma Sues Opioid Drugmakers for 'Fraudulent' Marketing Campaigns - - June 30 at 8:37 PM logoOklahoma becomes fourth U.S. state to sue opioid drugmakers - June 30 at 3:33 PM logoBill Ackman's Big Triumph Becomes His Big Problem - Bloomberg - June 27 at 3:23 PM logoAllergan Introduces REFRESH OPTIVE® MEGA-3 Enhanced with Flaxseed Oil, Latest Innovation in the REFRESH ... - PR Newswire (press release) - June 27 at 3:23 PM logoAllergan to Acquire Keller Medical, Inc., Adding Keller Funnel® to Company's Leading Plastic Surgery Portfolio - PR Newswire (press release) - June 7 at 8:24 PM logoAmgen: FDA Committee To Review Data Supporting BLA For ABP 215 - June 7 at 3:21 PM logoAllergan to Present New Data on Chronic Migraine at the American Headache Society Meeting in Boston - June 7 at 3:21 PM logoAmgen And Allergan Announce FDA Advisory Committee Meeting To Review ABP 215, A Biosimilar Candidate To Bevacizumab - June 7 at 3:21 PM logoAllergan to Present at the Goldman Sachs Global Healthcare Conference - June 2 at 3:53 PM logoStates Are Firing Back At Opioid Drug Producers - Benzinga - June 1 at 3:26 PM logoOhio sues five drug companies over opioid crisis - Reuters - May 31 at 3:20 PM



Allergan plc (ACT) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by Staff